Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) Operating Expenses: 2012-2025

Historic Operating Expenses for Agios Pharmaceuticals (AGIO) over the last 14 years, with Sep 2025 value amounting to $129.7 million.

  • Agios Pharmaceuticals' Operating Expenses rose 16.08% to $129.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $520.4 million, marking a year-over-year increase of 18.31%. This contributed to the annual value of $462.2 million for FY2024, which is 10.50% up from last year.
  • Agios Pharmaceuticals' Operating Expenses amounted to $129.7 million in Q3 2025, which was down 7.00% from $139.5 million recorded in Q2 2025.
  • Over the past 5 years, Agios Pharmaceuticals' Operating Expenses peaked at $139.5 million during Q2 2025, and registered a low of $91.2 million during Q3 2021.
  • Its 3-year average for Operating Expenses is $115.0 million, with a median of $113.4 million in 2023.
  • The largest annual percentage gain for Agios Pharmaceuticals' Operating Expenses in the last 5 years was 323.27% (2021), contrasted with its biggest fall of 29.99% (2021).
  • Quarterly analysis of 5 years shows Agios Pharmaceuticals' Operating Expenses stood at $104.8 million in 2021, then dropped by 1.28% to $103.5 million in 2022, then rose by 9.56% to $113.4 million in 2023, then grew by 19.75% to $135.8 million in 2024, then climbed by 16.08% to $129.7 million in 2025.
  • Its last three reported values are $129.7 million in Q3 2025, $139.5 million for Q2 2025, and $115.4 million during Q1 2025.